Stephen R Marder

Title(s)Professor-in-Residence, Psychiatry and Biobehavioral Sciences
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Stephen Marder holds the Dr. Daniel X. Freedman Administrative Chair in Academic Psychiatry.

    Collapse Research 
    Collapse Research Activities and Funding
    Enhancing Community Integration for Homeless Veterans
    NIH I50RX003437Oct 1, 2020 - Sep 30, 2025
    Role: Co-Principal Investigator
    Enhancing Social Cognitive Training with Oxytocin: Linking Target Engagement to Clinical Effects
    NIH R33MH107564Aug 15, 2015 - Aug 31, 2021
    Role: Principal Investigator
    Enhancing Social Cognitive Training with Oxytocin: Linking Target Engagement to Clinical Effects
    NIH R21MH107564Aug 15, 2015 - Aug 31, 2017
    Role: Principal Investigator
    Enhancing Community Integration for Homeless Veterans
    NIH I50RX001875May 1, 2015 - Sep 30, 2020
    Role: Co-Principal Investigator
    Opportunities for Innovative Drug Development for Schizophrenia
    NIH R13MH085413Aug 12, 2009 - Jul 31, 2011
    Role: Principal Investigator
    Relapse Prevention: Long-Acting Atypical Antipsychotics
    NIH U01MH070012Feb 1, 2006 - Dec 31, 2011
    Role: Co-Principal Investigator
    TREATMENT OF NEGATIVE SYMPTOMS &COGNITIVE IMPAIRMENTS
    NIH R01MH059750Jan 15, 2000 - Jul 31, 2005
    Role: Principal Investigator
    NEW ANTIPSYCHOTICS--CLINICAL TRIALS AND FOLLOWUP
    NIH R01MH046484Mar 1, 1992 - Feb 28, 1999
    Role: Principal Investigator
    MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    NIH R01MH041573Jul 1, 1986 - Jan 31, 2007
    Role: Principal Investigator
    TREATMENT UNITS FOR RESEARCH ON NEUROCOGNITION &SCHIZOPHRENIA (TURNS)
    NIH/NIMH N01MH41003Jul 31, 2009
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis. Lancet Psychiatry. 2024 01; 11(1):36-46. Siafis S, Brandt L, McCutcheon RA, Gutwinski S, Schneider-Thoma J, Bighelli I, Kane JM, Arango C, Kahn RS, Fleischhacker WW, McGorry P, Carpenter WT, Falkai P, Hasan A, Marder SR, Schooler N, Engel RR, Honer WG, Buchanan RW, Davidson M, Weiser M, Priller J, Davis JM, Howes OD, Correll CU, Leucht S. PMID: 38043562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments. Schizophr Res. 2023 08; 258:71-77. Marder SR, Umbricht D. PMID: 37517366.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    3. Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. J Subst Use Addict Treat. 2023 08; 151:209033. Zito MF, Fei Z, Zhu Y, Clingan SE, Marder SR, Mooney LJ. PMID: 37011880.
      View in: PubMed   Mentions: Translation:Humans
    4. Natural Language Processing: Its Potential Role in Clinical Care and Clinical Research. Schizophr Bull. 2022 09 01; 48(5):958-959. Marder SR. PMID: 35849122; PMCID: PMC9434436.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    5. N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study. Psychiatry Res Neuroimaging. 2022 Sep; 325:111515. Yang YS, Maddock RJ, Zhang H, Lee J, Hellemann G, Marder SR, Green MF. PMID: 35839558.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications. Psychiatry Res. 2022 07; 313:114590. Katz IR, Szymanski BR, Marder SR, Shotwell A, Hein TC, McCarthy JF, Bowersox NW. PMID: 35567853.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022 04; 604(7906):509-516. Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, Bass N, Bigdeli TB, Breen G, Bromet EJ, Buckley PF, Bunney WE, Bybjerg-Grauholm J, Byerley WF, Chapman SB, Chen WJ, Churchhouse C, Craddock N, Cusick CM, DeLisi L, Dodge S, Escamilla MA, Eskelinen S, Fanous AH, Faraone SV, Fiorentino A, Francioli L, Gabriel SB, Gage D, Gagliano Taliun SA, Ganna A, Genovese G, Glahn DC, Grove J, Hall MH, Hämäläinen E, Heyne HO, Holi M, Hougaard DM, Howrigan DP, Huang H, Hwu HG, Kahn RS, Kang HM, Karczewski KJ, Kirov G, Knowles JA, Lee FS, Lehrer DS, Lescai F, Malaspina D, Marder SR, McCarroll SA, McIntosh AM, Medeiros H, Milani L, Morley CP, Morris DW, Mortensen PB, Myers RM, Nordentoft M, O'Brien NL, Olivares AM, Ongur D, Ouwehand WH, Palmer DS, Paunio T, Quested D, Rapaport MH, Rees E, Rollins B, Satterstrom FK, Schatzberg A, Scolnick E, Scott LJ, Sharp SI, Sklar P, Smoller JW, Sobell JL, Solomonson M, Stahl EA, Stevens CR, Suvisaari J, Tiao G, Watson SJ, Watts NA, Blackwood DH, Børglum AD, Cohen BM, Corvin AP, Esko T, Freimer NB, Glatt SJ, Hultman CM, McQuillin A, Palotie A, Pato CN, Pato MT, Pulver AE, St Clair D, Tsuang MT, Vawter MP, Walters JT, Werge TM, Ophoff RA, Sullivan PF, Owen MJ, Boehnke M, O'Donovan MC, Neale BM, Daly MJ. PMID: 35396579; PMCID: PMC9805802.
      View in: PubMed   Mentions: 159     Fields:    Translation:Humans
    8. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022 04; 604(7906):502-508. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, Koopmans F, Magnusson S, Richards AL, Sidorenko J, Wu Y, Zeng J, Grove J, Kim M, Li Z, Voloudakis G, Zhang W, Adams M, Agartz I, Atkinson EG, Agerbo E, Al Eissa M, Albus M, Alexander M, Alizadeh BZ, Alptekin K, Als TD, Amin F, Arolt V, Arrojo M, Athanasiu L, Azevedo MH, Bacanu SA, Bass NJ, Begemann M, Belliveau RA, Bene J, Benyamin B, Bergen SE, Blasi G, Bobes J, Bonassi S, Braun A, Bressan RA, Bromet EJ, Bruggeman R, Buckley PF, Buckner RL, Bybjerg-Grauholm J, Cahn W, Cairns MJ, Calkins ME, Carr VJ, Castle D, Catts SV, Chambert KD, Chan RCK, Chaumette B, Cheng W, Cheung EFC, Chong SA, Cohen D, Consoli A, Cordeiro Q, Costas J, Curtis C, Davidson M, Davis KL, de Haan L, Degenhardt F, DeLisi LE, Demontis D, Dickerson F, Dikeos D, Dinan T, Djurovic S, Duan J, Ducci G, Dudbridge F, Eriksson JG, Fañanás L, Faraone SV, Fiorentino A, Forstner A, Frank J, Freimer NB, Fromer M, Frustaci A, Gadelha A, Genovese G, Gershon ES, Giannitelli M, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, González Peñas J, González-Pinto A, Gopal S, Gratten J, Green MF, Greenwood TA, Guillin O, Gülöksüz S, Gur RE, Gur RC, Gutiérrez B, Hahn E, Hakonarson H, Haroutunian V, Hartmann AM, Harvey C, Hayward C, Henskens FA, Herms S, Hoffmann P, Howrigan DP, Ikeda M, Iyegbe C, Joa I, Julià A, Kähler AK, Kam-Thong T, Kamatani Y, Karachanak-Yankova S, Kebir O, Keller MC, Kelly BJ, Khrunin A, Kim SW, Klovins J, Kondratiev N, Konte B, Kraft J, Kubo M, Kucinskas V, Kucinskiene ZA, Kusumawardhani A, Kuzelova-Ptackova H, Landi S, Lazzeroni LC, Lee PH, Legge SE, Lehrer DS, Lencer R, Lerer B, Li M, Lieberman J, Light GA, Limborska S, Liu CM, Lönnqvist J, Loughland CM, Lubinski J, Luykx JJ, Lynham A, Macek M, Mackinnon A, Magnusson PKE, Maher BS, Maier W, Malaspina D, Mallet J, Marder SR, Marsal S, Martin AR, Martorell L, Mattheisen M, McCarley RW, McDonald C, McGrath JJ, Medeiros H, Meier S, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mitjans M, Molden E, Molina E, Molto MD, Mondelli V, Moreno C, Morley CP, Muntané G, Murphy KC, Myin-Germeys I, Nenadic I, Nestadt G, Nikitina-Zake L, Noto C, Nuechterlein KH, O'Brien NL, O'Neill FA, Oh SY, Olincy A, Ota VK, Pantelis C, Papadimitriou GN, Parellada M, Paunio T, Pellegrino R, Periyasamy S, Perkins DO, Pfuhlmann B, Pietiläinen O, Pimm J, Porteous D, Powell J, Quattrone D, Quested D, Radant AD, Rampino A, Rapaport MH, Rautanen A, Reichenberg A, Roe C, Roffman JL, Roth J, Rothermundt M, Rutten BPF, Saker-Delye S, Salomaa V, Sanjuan J, Santoro ML, Savitz A, Schall U, Scott RJ, Seidman LJ, Sharp SI, Shi J, Siever LJ, Sigurdsson E, Sim K, Skarabis N, Slominsky P, So HC, Sobell JL, Söderman E, Stain HJ, Steen NE, Steixner-Kumar AA, Stögmann E, Stone WS, Straub RE, Streit F, Strengman E, Stroup TS, Subramaniam M, Sugar CA, Suvisaari J, Svrakic DM, Swerdlow NR, Szatkiewicz JP, Ta TMT, Takahashi A, Terao C, Thibaut F, Toncheva D, Tooney PA, Torretta S, Tosato S, Tura GB, Turetsky BI, Üçok A, Vaaler A, van Amelsvoort T, van Winkel R, Veijola J, Waddington J, Walter H, Waterreus A, Webb BT, Weiser M, Williams NM, Witt SH, Wormley BK, Wu JQ, Xu Z, Yolken R, Zai CC, Zhou W, Zhu F, Zimprich F, Atbasoglu EC, Ayub M, Benner C, Bertolino A, Black DW, Bray NJ, Breen G, Buccola NG, Byerley WF, Chen WJ, Cloninger CR, Crespo-Facorro B, et al. PMID: 35396580; PMCID: PMC9392466.
      View in: PubMed   Mentions: 460     Fields:    Translation:Humans
    9. Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar; 55(2):e1. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopecek M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertugrul A, Anil Yagcioglu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Radulescu FS, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubala WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. PMID: 35052001.
      View in: PubMed   Mentions:    Fields:    
    10. Examining racial differences in community integration between black and white homeless veterans. Psychiatry Res. 2022 02; 308:114385. Novacek DM, Wynn JK, Gabrielian S, Glynn SM, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar C, Green MF. PMID: 34999292.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar; 55(2):73-86. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopecek M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertugrul A, Anil Yagcioglu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Radulescu FS, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubala WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. PMID: 34911124.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    12. PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients. J Clin Psychiatry. 2021 09 21; 82(5). Le Moigne A, Csernansky J, Leadbetter RA, Andorn AC, Graham JA, Heath AT, Walling DP, Newcomer JW, Marder SR. PMID: 34551218.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Changing the Face of Schizophrenia. Am J Psychiatry. 2021 07; 178(7):584-585. Marder SR. PMID: 34270342.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Antipsychotic discontinuation and recovery: chicken or egg? Psychol Med. 2023 02; 53(3):1134-1135. Pierre JM, Zito MF, Yang YS, Marder SR. PMID: 37132647.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 Jan; 2(1):sgab014. Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. PMID: 34901863; PMCID: PMC8650077.
      View in: PubMed   Mentions: 1  
    16. Stigma-Personal Views. Schizophr Bull. 2021 01 23; 47(1):1-2. Saks ER, Marder SR. PMID: 32964221; PMCID: PMC7825016.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophr Res. 2021 04; 230:87-94. Li X, Guo X, Fan X, Feng T, Wang C, Yao Z, Xu X, Chen Z, Wang H, Xie S, He J, Zhuo K, Xiang Q, Cen H, Wang J, Smith RC, Jin H, Keshavan MS, Marder SR, Davis JM, Jiang K, Xu Y, Liu D. PMID: 33279374.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    18. The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (Am Psychiatr Publ). 2020 Oct; 18(4):456-465. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. PMID: 33343259; PMCID: PMC7725153.
      View in: PubMed   Mentions: 5  
    19. Motivational and cognitive factors linked to community integration in homeless veterans: study 1 - individuals with psychotic disorders. Psychol Med. 2022 Jan; 52(1):169-177. Green MF, Wynn JK, Gabrielian S, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar CA. PMID: 32517838.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Motivational and cognitive factors linked to community integration in homeless veterans: Study 2 - clinically diverse sample. Psychol Med. 2021 12; 51(16):2915-2922. Wynn JK, Gabrielian S, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar CA, Green MF. PMID: 32466807.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020 05 19; 81(3). Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G, American Society of Clinical Psychopharmacology, Pharmakopsychiatrie TTDMTFOTAFNU. PMID: 32433836.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    22. A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectr. 2021 08; 26(4):345-353. Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF. PMID: 32419679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology. 2020 10; 45(11):1842-1850. Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA. PMID: 32403118; PMCID: PMC7608251.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    24. Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatr. 2020 Feb 14; 1-6. Marder SR, Eriksson H, Zhao Y, Hobart M. PMID: 32054559.
      View in: PubMed   Mentions: 4     Fields:    
    25. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 Jan 07; 6(1):1. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. PMID: 31911624; PMCID: PMC6946650.
      View in: PubMed   Mentions: 89  
    26. Rethinking the risks and benefits of long-term maintenance in schizophrenia. Schizophr Res. 2020 Nov; 225:77-81. Zito MF, Marder SR. PMID: 31806525.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. J Clin Psychopharmacol. 2019 Nov/Dec; 39(6):620-627. Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, O'Brien CF. PMID: 31688452.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    28. The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophr Res Cogn. 2020 Mar; 19:100161. Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, Kern RS, McMahon RP, Robinson J, Marder SR, Keefe RSE. PMID: 31832342; PMCID: PMC6889798.
      View in: PubMed   Mentions: 2  
    29. Schizophrenia. N Engl J Med. 2019 10 31; 381(18):1753-1761. Marder SR, Cannon TD. PMID: 31665579.
      View in: PubMed   Mentions: 146     Fields:    Translation:Humans
    30. Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Mol Psychiatry. 2020 10; 25(10):2455-2467. Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, O'Dushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL, Consortium on the Genetics of Schizophrenia (COGS) Investigators, Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA, Genomic Psychiatry Cohort (GPC) Consortium, Fanous AH, Pato MT, McCarroll SA, Pato CN. PMID: 31591465; PMCID: PMC7515843.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    31. Brain glutathione levels and age at onset of illness in chronic schizophrenia. Acta Neuropsychiatr. 2019 Dec; 31(6):343-347. Yang YS, Maddock RJ, Lee J, Zhang H, Hellemann G, Narr KL, Marder SR, Green MF. PMID: 31364526.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Evaluating visual neuroplasticity with EEG in schizophrenia outpatients. Schizophr Res. 2019 10; 212:40-46. Wynn JK, Roach BJ, McCleery A, Marder SR, Mathalon DH, Green MF. PMID: 31434625; PMCID: PMC6791734.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    33. Motivational and cognitive correlates of community integration in homeless veterans entering a permanent supported housing program. Am J Orthopsychiatry. 2020; 90(2):181-192. Horan WP, Wynn JK, Gabrielian S, Glynn SM, Hellemann GS, Kern RS, Lee J, Marder SR, Sugar CA, Green MF. PMID: 31021133; PMCID: PMC6814490.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019 03 05; 80(2). Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. PMID: 30840788.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    35. History of Psychopharmacology. Annu Rev Clin Psychol. 2019 05 07; 15:25-50. Braslow JT, Marder SR. PMID: 30786241.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    36. N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study. Schizophr Res. 2019 06; 208:479-480. Yang YS, Davis MC, Wynn JK, Hellemann G, Green MF, Marder SR. PMID: 30712814.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm. Psychol Med. 2019 05; 49(7):1195-1206. McCleery A, Mathalon DH, Wynn JK, Roach BJ, Hellemann GS, Marder SR, Green MF. PMID: 30642411; PMCID: PMC6499668.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    38. Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. Biol Psychiatry. 2019 07 15; 86(2):110-119. Charney AW, Stahl EA, Green EK, Chen CY, Moran JL, Chambert K, Belliveau RA, Forty L, Gordon-Smith K, Lee PH, Bromet EJ, Buckley PF, Escamilla MA, Fanous AH, Fochtmann LJ, Lehrer DS, Malaspina D, Marder SR, Morley CP, Nicolini H, Perkins DO, Rakofsky JJ, Rapaport MH, Medeiros H, Sobell JL, Backlund L, Bergen SE, Juréus A, Schalling M, Lichtenstein P, Knowles JA, Burdick KE, Jones I, Jones LA, Hultman CM, Perlis R, Purcell SM, McCarroll SA, Pato CN, Pato MT, Di Florio A, Craddock N, Landén M, Smoller JW, Ruderfer DM, Sklar P. PMID: 30686506; PMCID: PMC6586545.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    39. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophr Res. 2019 04; 206:291-299. Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. PMID: 30478008.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    40. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 01; 29(1):127-136. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. PMID: 30470662.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    41. Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs. Schizophr Bull. 2018 10 17; 44(6):1217-1226. Reddy LF, Horan WP, Barch DM, Buchanan RW, Gold JM, Marder SR, Wynn JK, Young J, Green MF. PMID: 29140501; PMCID: PMC6192468.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    42. Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses. Schizophr Bull. 2018 10 17; 44(6):1204-1216. Anderson AE, Marder S, Reise SP, Savitz A, Salvadore G, Fu DJ, Li Q, Turkoz I, Han C, Bilder RM. PMID: 29420822; PMCID: PMC6192503.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. A dose-finding study of oxytocin using neurophysiological measures of social processing. Neuropsychopharmacology. 2019 01; 44(2):289-294. Wynn JK, Green MF, Hellemann G, Reavis EA, Marder SR. PMID: 30082892; PMCID: PMC6300532.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    44. "Will I need to take these medications for the rest of my life?" World Psychiatry. 2018 Jun; 17(2):165-166. Marder SR, Zito MF. PMID: 29856554; PMCID: PMC5980574.
      View in: PubMed   Mentions: 5  
    45. Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up. Psychiatry Res. 2018 09; 267:140-147. Faerden A, Lyngstad SH, Simonsen C, Ringen PA, Papsuev O, Dieset I, Andreassen OA, Agartz I, Marder SR, Melle I. PMID: 29906681.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. The Importance of Adequately Powered Clinical Studies: Response to Khan et al. Am J Psychiatry. 2018 02 01; 175(2):188-189. Marder SR, Laughren T, Romano SJ. PMID: 29385831.
      View in: PubMed   Mentions:    Fields:    
    47. Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model. Innov Clin Neurosci. 2017 Dec 01; 14(11-12):41-53. Anderson AE, Reise SP, Marder SR, Mansolf M, Han C, Bilder RM. PMID: 29410936; PMCID: PMC5788250.
      View in: PubMed   Mentions:
    48. The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr Res. 2018 05; 195:572-573. Wynn JK, Green MF, Hellemann G, Karunaratne K, Davis MC, Marder SR. PMID: 28965778.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    49. A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). Schizophr Res. 2018 05; 195:327-333. Hurford IM, Ventura J, Marder SR, Reise SP, Bilder RM. PMID: 28918221.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    50. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. J Psychiatr Res. 2017 12; 95:299-307. Noordsy DL, Glynn SM, Sugar CA, O'Keefe CD, Marder SR. PMID: 28942217; PMCID: PMC5653420.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Why Are Innovative Drugs Failing in Phase III? Am J Psychiatry. 2017 Sep 01; 174(9):829-831. Marder SR, Laughren T, Romano SJ. PMID: 28859511.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    52. Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry. 2017 08 01; 74(8):807-814. Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. PMID: 28636694; PMCID: PMC5710557.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    53. Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus Meeting. J Clin Psychiatry. 2017 Jun; 78(6):e638-e647. Chappell PB, Stewart M, Alphs L, DiCesare F, DuBrava S, Harkavy-Friedman J, Lim P, Ratcliffe S, Silverman MM, Targum SD, Marder SR. PMID: 28682533.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. A Cruel Irony for Clinicians Who Treat Depression. Am J Psychiatry. 2017 05 01; 174(5):409-410. Marder SR, Gitlin MJ. PMID: 28457149.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 05 01; 174(5):476-484. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. PMID: 28320223.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    56. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 03 18; 389(10074):1103-1113. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. PMID: 28185672.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCTClinical Trials
    57. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017 Feb; 16(1):14-24. Marder SR, Galderisi S. PMID: 28127915; PMCID: PMC5269507.
      View in: PubMed   Mentions: 129  
    58. Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ). J Psychiatr Res. 2017 06; 89:48-54. Buck B, Iwanski C, Healey KM, Green MF, Horan WP, Kern RS, Lee J, Marder SR, Reise SP, Penn DL. PMID: 28160626.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    59. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 07 01; 82(1):8-16. Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. PMID: 28117049.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    60. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017 Oct; 29(5):278-290. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, Weiss C, Hobart M. PMID: 27846922.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    61. How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. Psychiatr Serv. 2017 Apr 01; 68(4):324-329. Cohen AN, Hamilton AB, Saks ER, Glover DL, Glynn SM, Brekke JS, Marder SR. PMID: 27842472.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. Psychiatr Serv. 2017 03 01; 68(3):271-277. Glynn SM, Marder SR, Noordsy DL, O'Keefe C, Becker DR, Drake RE, Sugar CA. PMID: 27799019.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017 04; 182:90-97. Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S. PMID: 27789188.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    64. Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility. Am J Geriatr Psychiatry. 2017 01; 25(1):11-12. Sultzer DL, Marder SR. PMID: 28231870.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 07 15; 80(2):84-86. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. PMID: 27346079; PMCID: PMC6150945.
      View in: PubMed   Mentions: 1     Fields:    
    66. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2016 11 03; 71:66-75. Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B. PMID: 27371157; PMCID: PMC6432789.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry. 2016 May; 77(5):628-34. Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM. PMID: 27035871.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    68. Alpha-7 nicotinic agonist improves cognition in schizophrenia. Evid Based Ment Health. 2016 05; 19(2):60. Marder SR. PMID: 26872633; PMCID: PMC10699426.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    69. Community Evidence of Clozapine's Effectiveness. Am J Psychiatry. 2016 Feb 01; 173(2):103-4. Marder SR. PMID: 26844790.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33. Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. PMID: 26362273; PMCID: PMC4681562.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    71. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Res. 2015 Oct 30; 229(3):760-70. Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. PMID: 26279130.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry. 2015 Aug; 72(8):822-9. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. PMID: 26107752; PMCID: PMC5065351.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansPHPublic Health
    73. Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophr Bull. 2015 Sep; 41(5):1045-54. Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. PMID: 26142081; PMCID: PMC4535649.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    74. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophr Bull. 2016 Mar; 42(2):335-43. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. PMID: 26071208; PMCID: PMC4753586.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    75. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015 May; 164(1-3):136-42. Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. PMID: 25728831.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    76. Ellen Stover. Neuropsychopharmacology. 2014 Dec; 39(13):3132. Nemeroff CB, Marder SR, Lieberman J. PMID: 25381709; PMCID: PMC4229591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset. Eur Neuropsychopharmacol. 2014 Oct; 24(10):1615-21. Dunayevich E, Chen CY, Marder SR, Rabinowitz J. PMID: 25172269.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    78. Learning from people with schizophrenia. Schizophr Bull. 2014 Nov; 40(6):1185-6. Marder SR, Freedman R. PMID: 24973131; PMCID: PMC4193727.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    79. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res. 2014 Aug 15; 218(1-2):219-24. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. PMID: 24809242.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    80. Perspective: Retreat from the radical. Nature. 2014 Apr 03; 508(7494):S18. Marder SR. PMID: 24695331.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    81. Schizophrenia--time to commit to policy change. Schizophr Bull. 2014 Apr; 40 Suppl 3:S165-94. Fleischhacker WW, Arango C, Arteel P, Barnes TR, Carpenter W, Duckworth K, Galderisi S, Halpern L, Knapp M, Marder SR, Moller M, Sartorius N, Woodruff P. PMID: 24778411; PMCID: PMC4002061.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    82. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014 Aug; 39(9):2070-7. Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR. PMID: 24637803; PMCID: PMC4104336.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    83. Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol. 2014 May; 24(5):737-43. Marder SR, Kirkpatrick B. PMID: 24275698.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    84. The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014 Sep; 40(5):1047-52. Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, Deshpande SN, Trivedi JK, Gautam S, Avasthi A, Kern RS, Marder SR. PMID: 24214931; PMCID: PMC4133666.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    85. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014 May; 24(5):788-99. Davis MC, Horan WP, Marder SR. PMID: 24252823.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    86. Clinical trials for negative symptoms--emerging directions and unresolved issues. Schizophr Res. 2013 Nov; 150(2-3):327. Marder SR, Rabinowitz J, Kapur S. PMID: 24209763.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013 Oct; 74(10):e21. Marder SR. PMID: 24229761.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    88. Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity. Schizophr Bull. 2013 Nov; 39(6):1211-8. Olbert CM, Penn DL, Kern RS, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. PMID: 24072806; PMCID: PMC3796091.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    89. Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. Schizophr Bull. 2013 Nov; 39(6):1201-10. Kern RS, Penn DL, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. PMID: 24072805; PMCID: PMC3796089.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    90. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013 Nov; 150(2-3):328-33. Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J. PMID: 24028744.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    91. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013 Nov; 150(2-3):346-52. Arango C, Garibaldi G, Marder SR. PMID: 23938176.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    92. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013 Nov; 150(2-3):339-42. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. PMID: 23899997.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    93. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013 Jul; 147(2-3):393-7. Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, Marder SR. PMID: 23676253.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    94. The genomic psychiatry cohort: partners in discovery. Am J Med Genet B Neuropsychiatr Genet. 2013 Jun; 162B(4):306-12. Pato MT, Sobell JL, Medeiros H, Abbott C, Sklar BM, Buckley PF, Bromet EJ, Escamilla MA, Fanous AH, Lehrer DS, Macciardi F, Malaspina D, McCarroll SA, Marder SR, Moran J, Morley CP, Nicolini H, Perkins DO, Purcell SM, Rapaport MH, Sklar P, Smoller JW, Knowles JA, Genomic Psychiatry Cohort Consortium, Pato CN. PMID: 23650244; PMCID: PMC3729260.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    95. Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res. 2013 Nov 30; 210(1):55-61. Faerden A, Barrett EA, Nesvåg R, Friis S, Finset A, Marder SR, Ventura J, Andreassen OA, Agartz I, Melle I. PMID: 23489592; PMCID: PMC4066735.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    96. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013 Jun; 38(7):1245-52. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA. PMID: 23325325; PMCID: PMC3656368.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    97. Clinician perceptions, expectations, and management of negative symptoms in schizophrenia. J Clin Psychiatry. 2013 Jan; 74(1):e01. Marder SR. PMID: 23419229.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    98. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn. 2012 Aug; 39(4):393-414. Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. PMID: 22767341; PMCID: PMC3400037.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    99. Clinical instruments to evaluate and guide treatment in schizophrenia. Handb Exp Pharmacol. 2012; (213):1-10. Marder SR. PMID: 23027410.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012 Apr; 136(1-3):25-31. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR. PMID: 22169248.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    101. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011 Dec; 72(12):1616-27. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. PMID: 22244023.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    102. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013 Mar; 39(2):417-35. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. PMID: 22114098; PMCID: PMC3576170.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    103. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011 Oct; 1236:30-43. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M. PMID: 22032400; PMCID: PMC3787879.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    104. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011 Aug; 45(8):1113-22. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF. PMID: 21377168; PMCID: PMC4064828.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    105. Lessons from MATRICS. Schizophr Bull. 2011 Mar; 37(2):233-4. Marder SR. PMID: 21325472; PMCID: PMC3044624.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    106. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011 Apr; 168(4):400-7. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. PMID: 21285142.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    107. Methodological issues in negative symptom trials. Schizophr Bull. 2011 Mar; 37(2):250-4. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. PMID: 21270473; PMCID: PMC3044631.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    108. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011 Nov; 51(11):1587-91. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. PMID: 21209243.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    109. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011 Mar; 168(3):286-92. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR. PMID: 21205805; PMCID: PMC5069345.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansPHPublic Health
    110. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011 Mar; 126(1-3):124-31. Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR. PMID: 21159492; PMCID: PMC3050090.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    111. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011 Mar 01; 69(5):442-9. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR. PMID: 21145041; PMCID: PMC3058394.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    112. The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull. 2012 May; 38(3):630-41. Velligan DI, Rubin M, Fredrick MM, Mintz J, Nuechterlein KH, Schooler NR, Jaeger J, Peters NM, Buller R, Marder SR, Dube S. PMID: 21134973; PMCID: PMC3329974.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    113. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. PMID: 21105282.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    114. Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J. 2011 Apr; 47(2):123-35. Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. PMID: 20658320; PMCID: PMC3058510.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    115. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar; 37(2):300-5. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. PMID: 20558531; PMCID: PMC3044634.
      View in: PubMed   Mentions: 312     Fields:    Translation:Humans
    116. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011 Nov; 37(6):1209-17. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. PMID: 20410237; PMCID: PMC3196938.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    117. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull. 2011 Sep; 37(5):1057-65. Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. PMID: 20194249; PMCID: PMC3160227.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    118. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010 Apr; 71(4):433-41. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. PMID: 20156413.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    119. Apathy in first episode psychosis patients: one year follow up. Schizophr Res. 2010 Jan; 116(1):20-6. Faerden A, Finset A, Friis S, Agartz I, Barrett EA, Nesvåg R, Andreassen OA, Marder SR, Melle I. PMID: 19948392.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    120. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol. 2010 Jan; 50(1):73-80. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. PMID: 19843655; PMCID: PMC3648660.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    121. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009 Oct; 70(10):1348-57. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. PMID: 19906340.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    122. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011 May; 37(3):538-45. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. PMID: 19776205; PMCID: PMC3080688.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    123. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar; 35(2):347-61. Kern RS, Glynn SM, Horan WP, Marder SR. PMID: 19176470; PMCID: PMC2659313.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    124. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009 Jan; 70(1):25-35. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S. PMID: 19192472.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    125. Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiatry Rep. 2008 Aug; 10(4):352-8. Webber MA, Marder SR. PMID: 18627675.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    126. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov; 66(5):629-39. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. PMID: 18771484; PMCID: PMC2661978.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    127. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology. 2008; 41(5):271-8. Faerden A, Nesvåg R, Marder SR. PMID: 18594161.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    128. Treatment of agitation in patients with schizophrenia. J Clin Psychiatry. 2008 Jun; 69(6):e17. Marder SR. PMID: 18683992.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    129. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. PMID: 18371494.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    130. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008 Mar; 59(3):315-7. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. PMID: 18308914.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    131. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 Feb; 48(2):157-65. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. PMID: 18199892.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    132. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15; 32(4):984-8. Kim JH, Kim D, Marder SR. PMID: 18262321.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    133. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb; 165(2):203-13. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. PMID: 18172019.
      View in: PubMed   Mentions: 925     Fields:    Translation:Humans
    134. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008 Feb; 165(2):214-20. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. PMID: 18172018.
      View in: PubMed   Mentions: 281     Fields:    Translation:Humans
    135. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008 Feb; 165(2):221-8. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. PMID: 18172017.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    136. Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology. 2008 Jan; 22(1):100-9. Foerde K, Poldrack RA, Khan BJ, Sabb FW, Bookheimer SY, Bilder RM, Guthrie D, Granholm E, Nuechterlein KH, Marder SR, Asarnow RF. PMID: 18211159.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    137. Chronic restlessness with antipsychotics. Am J Psychiatry. 2007 Nov; 164(11):1648-54. Bratti IM, Kane JM, Marder SR. PMID: 17974927.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    138. Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MD. CNS Spectr. 2007 Nov; 12(11):812-5. Marder SR. PMID: 18084854.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    139. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 Nov; 68(11):1751-62. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. PMID: 18052569.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    140. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct; 164(10):1585-92. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff DL, Kee KS, Marder SR, Mintz J. PMID: 17898351.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    141. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct; 164(10):1593-602. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. PMID: 17898352.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    142. Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. Am J Psychiatry. 2007 Oct 01; 164(10):1585-1592. Sergi M, Green M, Widmark C, Reist C, Erhart S, Braff D, Kee K, Marder S, Mintz J. PMID: 22688151.
      View in: PubMed   Mentions: 6     Fields:    
    143. New paradigms for treatment development. Schizophr Bull. 2007 Sep; 33(5):1093-9. Stover EL, Brady L, Marder SR. PMID: 17673495; PMCID: PMC2632353.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    144. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. PMID: 17662577; PMCID: PMC2716219.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    145. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 Dec 15; 62(12):1363-70. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. PMID: 17601495.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    146. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007 May; 68(5):705-10. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. PMID: 17503979.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    147. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007 May; 68(5):662-8. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT. PMID: 17503974.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    148. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007 Apr; 58(4):482-8. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. PMID: 17412849.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    149. Lessons from each drug trial. Am J Psychiatry. 2007 Mar; 164(3):375-6. Marder SR. PMID: 17329457.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    150. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res. 2007 Feb; 90(1-3):316-24. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF. PMID: 17141477.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    151. Switch or stay? Am J Psychiatry. 2006 Dec; 163(12):2032-3. Davis JM, Marder SR, Tamminga CA. PMID: 17151147.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    152. Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 01; 847(2):237-44. Aravagiri M, Marder SR, Pollock B. PMID: 17098485.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    153. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J Clin Psychiatry. 2006 Jul; 67(7):e03. Marder SR. PMID: 17107228.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    154. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006 Apr; 32(2):234-7. Erhart SM, Marder SR, Carpenter WT. PMID: 16492797; PMCID: PMC2632230.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    155. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006 Apr; 32(2):214-9. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. PMID: 16481659; PMCID: PMC2632223.
      View in: PubMed   Mentions: 414     Fields:    Translation:Humans
    156. Commentary on "TM and our models of informed consent" by Charles W. Lidz. Behav Sci Law. 2006; 24(4):547-52. Charuvastra A, Marder S. PMID: 16883615.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    157. Drug initiatives to improve cognitive function. J Clin Psychiatry. 2006; 67 Suppl 9:31-5; discussion 36-42. Marder SR. PMID: 16965187.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    158. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006; 67 Suppl 10:13-21. Marder SR. PMID: 16965191.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    159. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006; 8(1):109-13. Marder SR. PMID: 16640121; PMCID: PMC3181758.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    160. Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. J Clin Psychiatry. 2005 Aug; 66(8):968-73. Erhart SM, Young AS, Marder SR, Mintz J. PMID: 16086610.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    161. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry. 2005 May; 162(5):1013-6. McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, Schooler NR, Kane JM. PMID: 15863811.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    162. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005 May; 66(5):638-41. Glick ID, Marder SR. PMID: 15889952.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    163. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol. 2005 Apr; 25(2):170-4. Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. PMID: 15738749.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    164. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005 Mar; 162(3):441-9. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. PMID: 15741458.
      View in: PubMed   Mentions: 560     Fields:    Translation:Humans
    165. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl. 2005; (427):43-6. Marder SR. PMID: 15877721.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    166. Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry Res. 2004 Dec 15; 132(2):117-30. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. PMID: 15598546.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    167. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004 Dec 15; 72(1):5-9. Marder SR, Fenton W. PMID: 15531402.
      View in: PubMed   Mentions: 142     Fields:    Translation:Humans
    168. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004 Nov 01; 71(1):83-95. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ. PMID: 15374576.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    169. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004 Sep 01; 56(5):301-7. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. PMID: 15336511.
      View in: PubMed   Mentions: 290     Fields:    Translation:Humans
    170. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004 Aug; 161(8):1334-49. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. PMID: 15285957.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    171. Panic disorder: psychopathology, medical management and dental implications. J Am Dent Assoc. 2004 Jun; 135(6):771-8; quiz 796-7. Friedlander AH, Marder SR, Sung EC, Child JS. PMID: 15270162.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    172. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004 Apr; 65(4):500-8. Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. PMID: 15119912.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    173. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry. 2004 Feb; 161(2):364-7. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. PMID: 14754789.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    174. Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Am J Psychiatry. 2004 Jan; 161(1):25. Marder SR, Fenton W, Youens K. PMID: 14702244.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    175. Posttraumatic stress disorder: psychopathology, medical management, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jan; 97(1):5-11. Friedlander AH, Friedlander IK, Marder SR. PMID: 14716250.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    176. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003 Dec; 25(6):657-64. Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. PMID: 14639051.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    177. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003 Aug; 160(8):1405-12. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE. PMID: 12900301.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    178. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul; 60(7):681-90. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. PMID: 12860772.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    179. Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1099-112. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. PMID: 12814861.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    180. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 01; 61(2-3):123-36. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. PMID: 12729864.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    181. Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc. 2003 Jun; 134(6):731-40. Friedlander AH, Marder SR, Pisegna JR, Yagiela JA. PMID: 12839410; PMCID: PMC6736549.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    182. Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry. 2003; 64 Suppl 16:41-6. Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. PMID: 14680418.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    183. Overview of partial compliance. J Clin Psychiatry. 2003; 64 Suppl 16:3-9. Marder SR. PMID: 14680412.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    184. Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry. 2003 Jan 01; 53(1):12-24. Quintana J, Wong T, Ortiz-Portillo E, Kovalik E, Davidson T, Marder SR, Mazziotta JC. PMID: 12513941.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    185. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002 Dec; 63(12):1180 -1. Tsuang J, Marder SR, Han A, Hsieh W. PMID: 12530415.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    186. Sexual side effects of novel antipsychotic medications. Schizophr Res. 2002 Jul 01; 56(1-2):25-30. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. PMID: 12084416.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    187. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002 May; 63(5):420-4. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM. PMID: 12019667.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    188. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry. 2002 May; 159(5):829-37. Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing WC, Wirshing DA, Ross D, Mintz J. PMID: 11986138.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    189. The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc. 2002 May; 133(5):603-10; quiz 624-5. Friedlander AH, Marder SR. PMID: 12036166.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    190. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002 Apr; 159(4):554-60. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. PMID: 11925292.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    191. In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry. 2002; 65(2):137-55. Liberman RP, Glynn S, Blair KE, Ross D, Marder SR. PMID: 12108138.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    192. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002 Jan 01; 53(1-2):25-30. Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J. PMID: 11728835.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    193. Antipsychotic drugs and relapse prevention. Schizophr Res. 1999 Mar 01; 35 Suppl:S87-92. Marder SR. PMID: 10190229.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    194. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996 Dec; 153(12):1585-92. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. PMID: 8942455.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    Stephen's Networks
    Concepts (484)
    Derived automatically from this person's publications.
    _
    Co-Authors (58)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _